Vera Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright assumed coverage of Vera Therapeutics (VERA) with a Buy rating and $75 price target Vera is a clinical-stage biopharmaceutical company developing novel therapies for serious immunological diseases, the analyst tells investors in a research note. The firm says positive ORIGIN 3 topline data could pave the way for atacicept’s accelerated approval for the treatment of immunoglobulin A nephropathy. It believes the significant market potential as well as a clear regulatory pathway for accelerated approval om IgAN could potentially make Vera an acquisition target if ORIGIN 3 is successful.